Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2) - Dataset (ID:20272)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule 1 | Small Molecule 2 | Small Mol 1 Concentration | Small Mol 2 Concentration | Small Mol Conc Unit | Time Point | Time Point Unit | Replicate | Total Number of Cells (Nuclei) | Number of Apoptotic Cells | Relative Viability | Mean Relative Viability | Apoptosis Fraction | Mean Apoptosis Fraction |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COLO 858 | Vemurafenib | Defactinib | 3.160 | 0.316 | uM | 72 | hr | 1 | 1556 | 1484 | 0.0085 | 0.0082 | 0.9537 | 0.9545 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 0.316 | uM | 72 | hr | 3 | 1488 | 1416 | 0.0085 | 0.0082 | 0.9516 | 0.9545 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 1.000 | uM | 72 | hr | 3 | 1093 | 1032 | 0.0087 | 0.0084 | 0.9442 | 0.9531 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 1.000 | uM | 72 | hr | 1 | 1509 | 1433 | 0.0090 | 0.0077 | 0.9496 | 0.9513 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 1 | 1247 | 1183 | 0.0091 | 0.0097 | 0.9487 | 0.9430 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 0.316 | uM | 72 | hr | 2 | 736 | 681 | 0.0093 | 0.0093 | 0.9253 | 0.9244 |
COLO 858 | Vemurafenib | PF562271 | 0.316 | 3.160 | uM | 72 | hr | 1 | 526 | 473 | 0.0096 | 0.0109 | 0.8992 | 0.8930 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 1.000 | uM | 72 | hr | 2 | 832 | 777 | 0.0099 | 0.0092 | 0.9339 | 0.9423 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 3 | 1115 | 1046 | 0.0099 | 0.0097 | 0.9381 | 0.9430 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 2 | 1231 | 1160 | 0.0101 | 0.0097 | 0.9423 | 0.9430 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 1 | 955 | 894 | 0.0101 | 0.0089 | 0.9361 | 0.9423 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 0.316 | uM | 72 | hr | 3 | 833 | 776 | 0.0103 | 0.0125 | 0.9316 | 0.9029 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 1.000 | uM | 72 | hr | 1 | 1199 | 1142 | 0.0103 | 0.0092 | 0.9525 | 0.9423 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 3 | 1041 | 978 | 0.0104 | 0.0089 | 0.9395 | 0.9423 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 1.000 | uM | 72 | hr | 2 | 1142 | 1078 | 0.0108 | 0.0099 | 0.9440 | 0.9514 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 1.000 | uM | 72 | hr | 1 | 1539 | 1471 | 0.0115 | 0.0099 | 0.9558 | 0.9514 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 0.316 | uM | 72 | hr | 1 | 694 | 626 | 0.0115 | 0.0093 | 0.9020 | 0.9244 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 1.000 | uM | 72 | hr | 3 | 954 | 881 | 0.0121 | 0.0156 | 0.9235 | 0.9257 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 0.316 | uM | 72 | hr | 2 | 639 | 572 | 0.0121 | 0.0125 | 0.8951 | 0.9029 |
COLO 858 | Vemurafenib | Defactinib | 1.000 | 3.160 | uM | 72 | hr | 1 | 933 | 827 | 0.0126 | 0.0137 | 0.8864 | 0.8777 |
COLO 858 | Vemurafenib | Dasatinib | 1.000 | 0.316 | uM | 72 | hr | 3 | 1258 | 1166 | 0.0131 | 0.0153 | 0.9269 | 0.8976 |
COLO 858 | Vemurafenib | Defactinib | 1.000 | 3.160 | uM | 72 | hr | 3 | 864 | 753 | 0.0132 | 0.0137 | 0.8715 | 0.8777 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 0.316 | uM | 72 | hr | 3 | 958 | 874 | 0.0139 | 0.0166 | 0.9123 | 0.8947 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 1.000 | uM | 72 | hr | 2 | 1272 | 1188 | 0.0139 | 0.0156 | 0.9340 | 0.9257 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 0.316 | uM | 72 | hr | 2 | 911 | 825 | 0.0143 | 0.0166 | 0.9056 | 0.8947 |